Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Cefamandole. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC22A6 | Q4U2R8 | 2/20 | 1.00 |
| ▸ | SLC22A8 | Q8TCC7 | 2/20 | 1.00 |
| ▸ | SLC22A11 | Q9NSA0 | 2/20 | 1.00 |
| ▸ | NR1I2 | O75469 | 2/20 | 1.00 |
| ▸ | PGR | P06401 | 2/20 | 1.00 |
| ▸ | PPARG | P37231 | 1/20 | 1.00 |
| ▸ | MAPT | P10636 | 10/20 | 0.87 |
| ▸ | TDP1 | Q9NUW8 | 10/20 | 0.87 |
| ▸ | POLB | P06746 | 10/20 | 0.87 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.87 |
| ▸ | HSD17B10 | Q99714 | 5/20 | 0.87 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.87 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.87 |
| ▸ | HPGD | P15428 | 1/20 | 0.87 |
| ▸ | APEX1 | P27695 | 1/20 | 0.87 |
| ▸ | PTPN7 | P35236 | 1/20 | 0.87 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.77 |
| ▸ | CTDSP1 | Q9GZU7 | 2/20 | 0.72 |
| ▸ | HTT | P42858 | 1/20 | 0.68 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cefamandole SCHEMBL28121696 | 1.00 | SLC22A6 (1.00) | SLC22A6SLC22A8SLC22A11NR1I2PGR | |
| Cefamandole SCHEMBL4401823 | 1.00 | SLC22A6 (1.00) | SLC22A6SLC22A8SLC22A11NR1I2PGR | |
| Cefamandole SCHEMBL11883501 | 1.00 | SLC22A6 (1.00) | SLC22A6SLC22A8SLC22A11NR1I2PGR | |
| Cefamandole SCHEMBL10604265 | 1.00 | SLC22A6 (1.00) | SLC22A6SLC22A8SLC22A11NR1I2PGR | |
| Cefamandole SCHEMBL17131900 | 1.00 | SLC22A6 (1.00) | SLC22A6SLC22A8SLC22A11NR1I2PGR | |
| Cefamandole SCHEMBL10478382 | 1.00 | SLC22A6 (1.00) | SLC22A6SLC22A8SLC22A11NR1I2PGR | |
| Cefamandole SCHEMBL14509205 | 1.00 | SLC22A6 (1.00) | SLC22A6SLC22A8SLC22A11NR1I2PGR | |
| Cefamandole SCHEMBL16072810 | 1.00 | SLC22A6 (1.00) | SLC22A6SLC22A8SLC22A11NR1I2PGR | |
| Cefamandole SCHEMBL10478386 | 1.00 | SLC22A6 (1.00) | SLC22A6SLC22A8SLC22A11NR1I2PGR | |
| Cefamandole SCHEMBL11735916 | 0.99 | SLC22A6 (0.98) | SLC22A6SLC22A8SLC22A11NR1I2PGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 23548 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12637481-B2 | Boronic acid derivatives and therapeutic uses thereof | QPEX BIOPHARMA, INC. (US) | 2026-05-26 | — | — | US | claimed |
| CN-115215923-B | Macrocyclic broad-spectrum antibiotics | 豪夫迈·罗氏有限公司 | 2026-05-19 | — | — | CN | claimed |
| US-20260108619-A1 | CONJUGATION LINKERS, CELL BINDING MOLECULE-DRUG CONJUGATES CONTAINING THE LINKERS, METHODS OF MAKING AND USES SUCH CONJUGATES WITH THE LINKERS | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2026-04-23 | — | — | US | claimed |
| US-12576124-B2 | Formulation of a conjugate of a tubulysin analog to a cell-binding molecule | HANGZHOU DAC BIOTECH CO., LTD (CN) | 2026-03-17 | — | — | US | claimed |
| EP-4676500-A2 | MICROBIAL CONSORTIA | Kanvas Biosciences, Inc (US) | 2026-01-14 | — | — | EP | claimed |
| EP-4659014-A1 | EMULSION-BASED THICK-FILM ANTIFOULING COATING FOR HIGHLY SENSITIVE ELECTROCHEMICAL SENSING | President And Fellows Of Harvard College (US) | 2025-12-10 | — | — | EP | claimed |
| US-12465623-B2 | Use of parasites and extracellular vesicles obtained from parasites in cancer treatment | YEDITEPE UNIVERSITESI (TR) | 2025-11-11 | — | — | US | claimed |
| US-20250339551-A1 | AN ANTIBODY-DRUG CONJUGATE HAVING TWO OR MORE DIFFERENT FUNCTIONAL SMALL MOLECULES FOR ENHANCED TREATMENT OF REFRACTORY DISEASES | HANGZHOU SEEHE BIOTECHNOLOGY CO., LTD (CN) | 2025-11-06 | — | — | US | claimed |
| EP-4642492-A1 | AN ANTIBODY-DRUG CONJUGATE HAVING TWO OR MORE FUNCTIONAL SMALL MOLECULE COMPOUNDS FOR ENHANCED TREATMENT OF REFRACTORY DISEASES | Hangzhou Seehe Biotechnology Co., Ltd (CN) | 2025-11-05 | — | — | EP | claimed |
| EP-4642484-A1 | TARGETED TREATMENT OF PROSTATE CANCERS AND OTHER TUMORS BY AN ANTIBODY-DRUG CONJUGATE | Hangzhou Seehe Biotechnology Co., Ltd (CN) | 2025-11-05 | — | — | EP | claimed |
| EP-0031561-A2 | A rectally administered suppository comprising a drug and an adjuvant | MERCK & CO. INC. (US) | 1981-07-08 | — | — | EP | claimed |
| EP-0029202-A1 | Novel tetrazole-5-thiol esters and process for preparing cefamandole using same | Asahi Kasei Kogyo Kabushiki Kaisha (JP) | 1981-05-27 | — | — | EP | claimed |
| EP-0007717-A1 | Clavulanic acid derivatives, a process for their preparation, their use, and pharmaceutical compositions containing them | BEECHAM GROUP PLC (GB) | 1980-02-06 | — | — | EP | claimed |
| US-4143134-A | BACTERICIDES, ANTIBIOTIC POTENTIATORS | HOFFMANN-LA ROCHE INC. (US) | 1979-03-06 | — | — | US | claimed |
| US-4115644-A | Process for preparing pure cefamandole from alkali metal and ammonium salts thereof | ELI LILLY AND COMPANY (US) | 1978-09-19 | — | — | US | claimed |
| US-4100275-A | PEPTIDES | HOFFMANN-LA ROCHE INC. (US) | 1978-07-11 | — | — | US | claimed |
| US-4035361-A | Bis-trimethylsilyl cefamandole and process therefor | ELI LILLY AND COMPANY (US) | 1977-07-12 | — | — | US | claimed |
| US-3947415-A | Cefamandole derivatives | ELI LILLY AND COMPANY (US) | 1976-03-30 | — | — | US | claimed |
| US-3947414-A | Cefamandole derivatives | ELI LILLY AND COMPANY (US) | 1976-03-30 | — | — | US | claimed |
| US-3937655-A | Method for preparing stable β-lactam-type-antibiotic susceptibility test discs | ELI LILLY AND COMPANY (US) | 1976-02-10 | — | — | US | claimed |